research Alopecia Areata after COVID-19 Vaccines
Some people with a history of autoimmune hair loss experienced worsening symptoms after COVID-19 vaccination.
Search
for
Sort by
Research
990-1000 / 1000+ results research Hair Follicle-Related MicroRNA-34a Serum Expression and rs2666433A/G Variant in Patients with Alopecia: A Cross-Sectional Analysis
Higher miR-34a levels and the A variant of the MIR-34A gene are linked to increased risk and severity of alopecia areata.
research Applications of Antioxidant Nanoparticles in Immune-Mediated Inflammatory Diseases
Antioxidant nanoparticles show promise for treating inflammatory diseases but need more research for safe and effective use.
research Serum-Based Assessment of Alopecia Areata Response to Treatment Using ATR-FTIR Spectroscopy
ATR-FTIR spectroscopy could help monitor alopecia areata treatment response non-invasively.
research Study of the Thyroid Profile of Patients with Alopecia
People with hair loss conditions may also have thyroid disorders, but more research is needed to understand the connection.
research Frontal fibrosing alopecia: A review of disease pathogenesis
The cause of Frontal fibrosing alopecia, a type of hair loss, is complex, likely involving immune responses and genetics, but is not fully understood.
research Mesenchymal Stem Cells for the Treatment of Skin Diseases
Mesenchymal stem cells show promise for treating various skin conditions and may help regenerate hair.
research Resolution of paraneoplastic alopecia areata following nivolumab in a patient with metastatic melanoma
Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.
research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
research A Case of Linear Alopecia of the Scalp
Treatment with methotrexate and prednisolone led to complete hair regrowth and no relapse for 2 years.